Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma

NCT05535023 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI Request

Conditions

Squamous Cell Carcinoma
Oropharynx Cancer
Head and Neck Cancer

Interventions

DRUG: SAR444245
DRUG: Cemiplimab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]